0001104659-22-028121.txt : 20220228 0001104659-22-028121.hdr.sgml : 20220228 20220228163040 ACCESSION NUMBER: 0001104659-22-028121 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220223 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20220228 DATE AS OF CHANGE: 20220228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36672 FILM NUMBER: 22690196 BUSINESS ADDRESS: STREET 1: 1371 EAST 2100 SOUTH STREET 2: SUITE 200 CITY: SALT LAKE CITY STATE: UT ZIP: 84105 BUSINESS PHONE: (781) 788-8869 MAIL ADDRESS: STREET 1: 1371 EAST 2100 SOUTH STREET 2: SUITE 200 CITY: SALT LAKE CITY STATE: UT ZIP: 84105 FORMER COMPANY: FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060811 8-K 1 tm227887d1_8k.htm FORM 8-K
0001372514 false 0001372514 2022-02-23 2022-02-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares












Date of report (Date of earliest event reported): February 23, 2022



(Exact name of registrant as specified in its charter)



(State or other jurisdiction of incorporation)


001-36672   98-0443284
(Commission File Number)   (IRS Employer Identification No.)


1371 East 2100 South

Suite 200

Salt Lake City, Utah 84105 



(Address of principal executive offices)   (Zip Code)


(781) 788-9043

(Registrant’s telephone number, including area code)


(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:
Common Stock, $0.01 par value   KPRX   The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.


On February 23, 2022, Kiora Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on the Nasdaq Stock Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”).


The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the Minimum Bid Requirement. To regain compliance with the Minimum Bid Requirement, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive trading days during this 180-day compliance period, unless the Staff exercises its discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(G). The compliance period for the Company will expire on August 22, 2022.


In the event that the Company does not regain compliance within the 180-day compliance period, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would need to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the Minimum Bid Requirement, and provide written notice to the Staff of its intention to cure the deficiency during the second compliance period. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company does not meet the other listing standards, the Staff could provide notice that the Company’s common stock will become subject to delisting. In the event the Company receives notice that its common stock is being delisted, the Nasdaq Listing Rules permit the Company to appeal any such delisting determination by the Staff to a Hearings Panel.


The Company intends to actively monitor the closing bid price of its common stock and is evaluating available options to regain compliance with the Minimum Bid Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Requirement or that the Company will otherwise remain in compliance with the other listing standards for the Nasdaq Stock Market.


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


As previously reported, Sarah Romano resigned as Chief Financial Officer of the Company effective as of February 25, 2022 (the “Effective Date”) to pursue another opportunity. Following Ms. Romano’s resignation, the Company appointed Michael Meluzio, CPA, the Corporate Controller of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Date.







Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


  By: /s/ Brian M. Strem, Ph.D.  
    Brian M. Strem, Ph.D.  
    President and Chief Executive Officer  
  Date: February 28, 2022  



EX-101.SCH 2 kprx-20220223.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 kprx-20220223_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 kprx-20220223_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Feb. 23, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 23, 2022
Entity File Number 001-36672
Entity Central Index Key 0001372514
Entity Tax Identification Number 98-0443284
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1371 East 2100 South
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Salt Lake City
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84105
City Area Code 781
Local Phone Number 788-9043
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol KPRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 tm227887d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001372514 2022-02-23 2022-02-23 iso4217:USD shares iso4217:USD shares 0001372514 false 8-K 2022-02-23 KIORA PHARMACEUTICALS, INC. DE 001-36672 98-0443284 1371 East 2100 South Suite 200 Salt Lake City UT 84105 84105 781 788-9043 false false false false Common Stock, $0.01 par value KPRX NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://eyegatepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm227887d1_8k.htm kprx-20220223.xsd kprx-20220223_lab.xml kprx-20220223_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm227887d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm227887d1_8k.htm" ] }, "labelLink": { "local": [ "kprx-20220223_lab.xml" ] }, "presentationLink": { "local": [ "kprx-20220223_pre.xml" ] }, "schema": { "local": [ "kprx-20220223.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "KPRX", "nsuri": "http://eyegatepharma.com/20220223", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm227887d1_8k.htm", "contextRef": "From2022-02-23to2022-02-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://eyegatepharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm227887d1_8k.htm", "contextRef": "From2022-02-23to2022-02-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 13 0001104659-22-028121-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-028121-xbrl.zip M4$L#!!0 ( -.#7%0'M!"TR,#(R,#(R,RYX MW@T\YY ML^F@D^-W;Y'YU=]CC"XIL*"&+H2/F[PGCM W$D(-?08.DF@AC] =8;&UB$O* M0*)S$48,-!A'&JF&]DM>A2",-]"] QX(>=MN3G4'6D>JYKJCT:C$Q1,9"3E4 M)5^$FPEV--&QFJJ5Q^7LMQG]BBI_2OY 3O='G\9M>M\'?A"W2/7!_T%HDW2O M@^>']@?R'*-P^ K MWN->#HT5[A,23>$]HKJ);.9(X+CLX:J74Y34RW!C+(9B/8E %1)25P'MZTW[ M?LJ "?2)AFA 9$ALLUJ"_5?-R#$(@>M+(<,+Z)&8F

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

IXT0 M]5\YTP:T6&%H'Q@C@;^F!.Y12,C\03.9<<<( _W0&DG]-](+$H]&0NRC&0CA M$CXF4;V]SAZ)_G=*]'Z=+P3^]9,[[]O3#9[_5A%D"/YX*2$X4$L8A3O07"7V M5*\1_ ^,D>1/*(>\"SF(G2JX$]EH61UYAC ML9/DIHTRR='_ TRCP6\98[&3I*L-$@F@]W.M=QP*CC!^:RQVDD2U220!]VMI MN%FYV8-/>3K^?N-UE_>A%98S27+J$T7&M[HS(8V;& DQWK?$=YBG3JQ&/FP>00ULL<)(,-"R0C/@# M6PX3JXQ/>#G-V S>6P3+GR3]1,DE"\-0QDK/U=;MYK[*[7=SU5=)<(AO*(@- M"4E>^@SI9(&Y3!*++%N_W' )W5 X:LW1\]#W\.C)\E7&V6^ M(/0GST-_@D=/DK,VRJ1&W[=O;_6#6GAFM;W&6.PD.6N#1&KHQ=GG5M]I]<3+ M55A-Y ]*8/$3IK)AL=0Q6)_\,;V^LL0R)TQKZ\51L[Y3F6'B7SYONLJLM\=R M)TQP0T(I;DR6\7M%7 M:9K+]7T=SPR;QQ2+F"1-#,HCP#U2@L?<<#G]:*\@-6>BGG6='18T25+H%T9 M^4Z#BSC82_-BS9C;^J!O)Q/?2!RRQU(GR0F;A=+3'V99#OJY,:@IA8T$27J( M%4TQYD"V-']PN'L^(L>7>L1[)EBX)!E@K1S"\>%Z&<^8G()_942])18R2488$DZ[3PI>!?5./WF.*A4ZSA3,DCP)WGG #2>G6@$LF8YMZ;?;<>3+YYE+8(-#L M\42*)ILB^ I"?)!J(4? ,B4A*=.!T"R!MP@V$H1SD@URR<+P18GB]\SQ!(G7();*XT,]"AE0ESE&9>0 M!<>9/4,L:,*UMK72R$!?IZ"G=I![K]7"S-;[3T/ /06PX E7U :ET@5@^7W? M>[DW+TB_QAK]1 5"]%Z1E(\,B6.W4*,\P\N$:0_YD#V6/>G&3[]0 OJW9@9Z M^]JJ<&AH\[O0@HKF4MA(D*2U6-%TY]NMIP\$3[<[=ECFA ELG3"Z?5SY6/!X M(!0+7K?OF&$9$V:K-;+($%\Q^:CSN8E7=UK% &X:)MM\\Q!)$[(";%@(\]AG MH:"[M:#2U&UP4O'C:&:%9[>Y*9[7:GT,WF (EL.&AW*3*4(XX=51]GT#&B17 MJWN8@'9+(!Y@::YL8X_ABR5$<6R,2)^,A,90$ZKSSH&N&WO /96W_,3]<4^> MM4?^!U!+ P04 " #3@UQ4D8:[F0,5 #H:0 $0 '1M,C(W.#@W9#%? M.&LN:'1M[3UI5^+,TM\]Q__0+_<^]^BY @F+XC+<@RS*J,@ SO;%TR0-])B% MR2+@KW^KNA-((+C,@XYSWW<6E71U575M757IQ)/_3$V#W#/'Y;;U(:5FE!1A MEF;KW!I^2/G>(%U*_:>\O74R\@ .8"WW0VKD>>.C;'8RF60F^8SM#+/JX>%A M=HHP*0ET-$V$RRF*FOUZ==G51LRD:6ZY'K4T-I]D<.MN/7X(FA1@GHA*'?M0DX]>(P/"3&?,%T'JR+/L$+V M];1SN0#WDN$7H%G/H98[L!V3>J!#Q%1,*[ET;C^").TR+88(/F>&]OV3>$KI MO!KB65%.?*4XW*?N7.(Z6Q)W2!,&8$9._5D(01TV6(MX/PNC(:#OIH>4CN? M ^KV!6 P(/"F%37"-8PXML'FP\HB#WC&:;. '_Y5/"ZQC5X3O!/R<>]PQ6/LG*[S!J,H\2 M1)1F/WU^_R%5M2V/65ZZ-QN#&C3YZ4/*8U,O*YTSB_.R =J3_TFG28,S0S\B M7>8=DQ8UV1&9ZM-CTJR)'VZ57.7VIOM7KG96J;3A&ZZ'I-//G9TOW.)Z;U?6 M>1NN\P7("K7YK%^97MR_96![L CX5[= C+,JR,>A1M/2V?2"S6X5B$_Y@UQ1 M+;P$[V$$;\5DE@[_O89!A[<#:KCL!:CV3T'8M5OU-@@;$B=<>@F.W&T7Q,S< MV]RMB)(2B2NNO01/#7EI![CR*RRM1=ZW]1EQO9G!/J0&8(-'1%7&'NEQ$T!: M;$(ZMDFM/7EA#QAP^$!8N\[OPWDZ=\<&G1T1R[:8&.33(S1;YJ _B$]LX,N#,(6(I+'$SJS8OXCI;GKP@ METVD%U ;@WQM?94+R"@H,N75$E!2D%F,Q'-T>.K[!TFTZ%+M8-$++ M>6G/'L/<,>PAP86^[7FV&5R;<-T;8?Q7_DK%9O=M!YB2LT\-JMV1'&P1KFUP M_9@$@R$F.:XNQG%32;O\ ;8LN)HJ_^L?ZKYR+)<7?(VL(!M;PMK%ATC&2R#/ MW<%" 8B5$^68H+.FJ<&'<$F#0,,<$$&_?--J]NHUTNU5>O7N2=\1X;5;K]YT MFKUFO4LJK1JI?ZV>5UIG=5*]OKIJ=KO-Z]9)ME]^?>:^5+KGS=99[[JU1VI5 MDE.*A<.-4GY2SH5-+:5QW;D*:+EC:HD @WG-H9(7Z5HZ7;,U'_=8S)9OM7EF MN<@Q'QIUW?PZL:OYQO#[5T3\*$>.(IT <-K8=C^R$GQF%+8BY'F'W !D,,WWW".N M\K+GY98\KRWRG+K,@I)=\'[?5XJY8670&_RR"T8S;ATHF3!OI-/9#+AG5I*+ MQAA+E1NL[_C4F9%:0AU5BLI:ZW>OK M]MVP6&JS#03*)+JI\D7SNE,A[?-*YZI2K=_TFM7*97>/-%O5S%NH(UEZ._4I MU3S!NW2/D&="7>*.F89UATXXB-=SB09Y($S;_=.\_Q%7EKIJ6IKM@.N+UF'7 M Z>IRB99U=;7F,RT4VKDK.G '(TVX=C8X<0BS&-CQ[Y'?<0]^QE\0I1C!IU M3/B-]B28(K9#;&\$U>X/W^&NSC7D%PV,1Q?PBG;DT;[!@"O#@)5KXF: DA*? MQU37P\\O)AJI!^9IOF8;!AV[D,R'/\GJ[\0+"Z 33P])W3/'XQHU0KE! 3'' M6CC\Z]GF>Q SWP8W&.BZSYQD6ZW9S%2^];Z?3K2-A;<%3>Q9J.G\_O[!X_N* MIS\M#UDSS462^VNAV>=,_U5QUF/B[-%I,^BY:,)0'Y.M>E@:G/V\NK<;=QN3 M[1H&4N7#4EHI%/*YTDI#;UG2\,5YH1DF^G/5-DWNXMTU@AHGDI/=EVCS%U28 MR$JS _FH.3;L&026N'Q(R\[L+JT[*V) >2/1Y?\#U?,\Z\VV[V+,82NZ[C#7 M#;Y=.VU(FB&W7).K?S+R?;5KC]7#PMOEZLD,ILHW'ET7"E:6O)^T MY+8-M(WO?+R^.+%KITY1&[.KSQLW_QCU5+E44)7B(Y$MW.[F3O 6:>#2]-?; MKQ)#5N$7E3;8M]F5^O&F]B/_FY6VN>UH$SO20LC+/&XTTPU$A57JV %7Y6-J M$#9EFN_Q>^R.0++)W-^2^8+B"&IN;8K[1[5B=M9%.=P-*@ZCZUVDFV]6/)57 M%6<3A6R47JI\4%+7N,3N2EP^#3B^M$%_[9%M/5I^7Q9O^JW\[#-K&!O@>IDF M !^IC!ZPR &V2:TA S_'#7][R\ R0-Y9V/WU3'"5 ME_DMZ\?N86]<*JER=<2T.^*-&*%C2( @6&++KV]/29\9]@0E@(,H)TF[E+X@ M VZ X@EWP0H\9NE,W][R;!"1Z1L>M9CMN\:,N%#-NX.9F!_,L/NP9AKV#W$@ MTJ3V 1'(WIJ%8P.H;.T)SL/4C&/?PCUZOR:6"I*'");T@)K#I"0A=RQ>TM:1%H"EW8N6$Z!V54-(_LJ >D MVNB07%[) .0[CCN_:!2EP"BZML$U6+^VP]!E M\6BD..*!$=JY'@S6I30/=\.[DO*]P)6-W/U::SSK^7J>$:VW)<"> M%634@I[.[?2#4QG/,B\YX?^H@962#:SINCYSGC2SFG;5:71GM=:WUXU13W'W MNXPMS]*%'>T%QA9,>-?&%MF892K''$B6HQ( "!1+((2%NP5)'JSZ%7.Z]W%' MYJG&PDHW8>G0:7_YT&E /Y]?UPM;]N[G/?: 9]?P>9Y00?([H]I(_J1!]8,9 M>'_A)$F]D'FC+YFYQ]HHSUVXLOF%.Q3M03+7G9E]V]C!!M'O7^OFE8QGF-;I MF 7A*!@/_'8RXB' PLU7+"':O7ND,99@\)M9/J MY0^4'Z7K!TXWT6Q?I@GU-FP54/UV/5N[VR/_5#**2L;4(??4\-T!5]7#?)[L(.#!L>A^A,!K"'#7FGXN)$>29]YR-UN.R)J&H7Z\DJL3N#X;T MSP3YJJ2>[*L7#Y6'R3TK30YSKUH-/<+8BPJA]ZSVYB#!T4+EXZV*1*_ERQWH M[:T1^"0SH& !G[1L4;[X+A-@H _1Z2;BU01<]+#EHY&H!D',F"'U"0?::'06 M< \C#KOG+LP#3Z>6AETNJHFG]A$8WPNA4T=W98M;C]1.HJ4>+Y[R.S1>/$5= M.+-!*P_MXD\Q@-_ZL& D94]\6##R,.'F'A9\W[)'GH\!_J>/31) *Q<@\J=5 M6:Y]MC*J*367H*I]%&+"$Y3Q6V7ALZ8KY!U&[])]!OX+/(X%SU&2OX ]JKT_ M17'AWS=HECS9$4FN#D,,>'1H-7X%_B34 L5MTV,FR4-=E7EN\5XJ+578/WS7 MXX/9,XBU;&!?/&U38P9L(^(FIT,:E!N^PT3[*[@+2@F^$(5;/H3XRP 2_1O! MN\$N<$QZXKTWD$H"Q@!J91FO<2HZ6#_LE SG*YDBMU[!Y*XMLO+XVAZYX+9# M25N\CD5COC (0-&TM S9P6T.CR'DE.,@;1&?U./=[2V':8S?@T"IR*0U#M%F M1@SF0:(:FRG5%$XD \BIQ/X9*N*3#YH?S!NX-08EN8>]W1@64--@,$<"&L*J M3=8\VUNBH@]JFSUR>5G%5%H2%Q#S>9!7@&TA540=K E^IC -,PF\*DX9Y!5, M!-WPS%+?=Z%6<*%HH#.0#H+UN8['FS063MS>BLA('-S09+_!%=R-J$XTP\9L M1-[=_Z>:411,8XAX*\ >$7T>+%P0O,&Z3,'V%E#UYO(A4?$$=_J#D9@S% M%!9*<'74W)OFK@)-36'!'TD?M MA#)]US6),!(9)C"]M&S"39/IXIP%&PP8%E]25/, ,HB:1JA*>9MAKDM\3D(( M, ..(E)*1\=WC,G\,U&V)579T79W\KL[E=V]F/4A8VH)[(T:#".1L#%4,"3' M4KV0W?(Y>DA-8?(:I61(;]T\\L@TR5!H:@O+3A9&8-?;6U(8)@1L,&E"/?!^ M])TEPQ;^0><&C<5NW+D\V4&2Z]:A1!;NR=T@\2XI:1@)FN"+--12YZ[F,%$R@$QE)2&KZJ""B-XO>4)U9[L9$7=6V%B) M 2!R P\]CD'":"X5?XABPHB+H1\D!MC8\Q<=9NYHCY+-C,N)C^J MNNVM4'=1O":=H17!3C[DF H)J['P.)BH]Z!T6W:2534(\_\I]I-9'/O$]@TH M*UD0.AGSI+I68F<88L4&A#R8,FR*'K$XTNKW#:X9X+>0:9+@?5>00A *"I?/ M:H*E>UAKAB@7A28BE#:VMW!*-M78&-<(<7OPN)LBG:!8)9/@2(\EXQLL:^$" M^("H%YP0"TU?$TD1@$2VZ[FW,0+N: /V535ER+D] 6-PQ)$\[N%A-48=-TYQ MQ4Z$ Z"=8&A A2:SL( M^R $^3@]W_@O@#LZF%:B6%>\A$ZQ8+9( ]R8Q3%,]Y1"A!N^DP$.8&3!<:? M$&]$7#)YG @P(Z1N8',# J\/B<*<._C)PRF6/-S7GT75 A/).:@+>PM0&EK, M>->QIQ=9M#S?*.R,:KA3@-.!1+D7)&J)^Q5(?FFS1I\!\3/T8"KD1>^A1! V M:8]ETKEVMWW,'<5> :M09CJH\41ZKJ^(^:B%4B+B?E#Q!=>3H^(=2>YF?". M"6QY@!730A)#O+TUQ[S&C>:Y;T+"N$ES>:43Q?.2\RKP-2JI8/N9W7-Y;CM\;PZ@H X=2;08+%R8 MA4>]H5BHCC@;D,:\I1V(:BE;#^H;3+"ID.RB^"_*)#16Y=7GT/BFFWG!#(%* MY,> Q)+!PQXCA_BNN5EF>ZLQ/R9^Y68";N=[K.1:[$KQ;(Q*$X&LZPI*7LH, MZ3:KH2P\O463/1N'*"SLL0]7%EBY;UX[FC1^;<#,Z_3'Y9.3[VMXXGKT2E> M3:?>?8-'F]["F),#>3M2XWA((J>^-; ?V M97USN==3KO\F*G_?!T+CJ5KRX2- AIG(AU3N&;G4H^\I6Y/)1=<4)[D*^MFR:D#E16YRD"E!'%DC[1'F5KF.:EY,2Z=#:GXZ9-RSY3# MDSIY]KK_Y%6V,7%%3")7E.EV??[\>I!N_Y>X[]^-3 MKY?Z+0[E_V[>OL(3<^*5^TIGG= M]$J?&Q=?#EK=:T_Y\>]./V?FFLU.M:L=%+3FS7?>G7IZTVU!)O'ETS?UR]<9 M;]RQ>NM,4[[>=\_[!V?MAZO2Q;[W+?=9N\\>5$:U6;Z M1?-._]RO^.[@XW?]KI8]_SHY+7SM?#R??/@@1?*_4$L! A0#% @ TX-< M5 >T%SH^ P ! P !$ ( ! &MP'-D4$L! A0#% @ TX-<5'X'8E/_"@ ;(< !4 ( ! M;0, &MP